Nintedanib Granted Breakthrough Therapy for Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim announced that the FDA has designated nintedanib Breakthrough Therapy designation for the treatment of idiopathic pulmonary fibrosis (IPF).

Nintedanib is a small molecule tyrosine kinase inhibitor (TKI) which targets growth factors that may be involved in pulmonary fibrosis, such as the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR).

Previously in 2011, nintedanib was granted Orphan Drug designation for the treatment of IPF. It was also granted Fast Track status in June of 2013 and Priority Review designation in June 2014.

For more information please call (800) 542-6257 or visit Boehringer-Ingelheim.com.

Want to read more?